. 2018 Dec 28;24(48):5462–5476. doi: 10.3748/wjg.v24.i48.5462

Table 1.

Assessed cecum lesion (sum of longest diameters, mm, at mucosal site (M) and serosal site (S), means ± SD) and adhesion severity (score 0-7, Min/Med/Max)

Medication (/kg, 10 ml/2 min bath/rat)	Assessed cecum lesion (sum of longest diameters, mm, means ± SD) and adhesion severity (score 0-9, Min/Med/Max)
	Day 1		Day 7
	Perforated cecum lesion	Adhesion severity	Perforated cecum lesion	Adhesion severity
0.9%NaCl (control)	5.0 ± 0.5 (M)	3/3/3	5.0 ± 0.5 (M)	3/4/4
0.9%NaCl (control)	5.0 ± 0.5 (S)	3/3/3	6.0 ± 0.5 (S)	3/4/4
BPC 157 (10 µg)	3.0 ± 0.0 (M)^a	1/1/1^a	0.0 ± 0.0 (M)^a	1/1/2^a
BPC 157 (10 µg)	3.0 ± 0.0 (S)^a	1/1/1^a	0.0 ± 0.0 (S)^a	1/1/2^a
L-NAME 5 mg	7.5 ± 0.4 (M)^a	5/6/6^a	8.0 ± 0.4 (M)^a	6/6/6^a
L-NAME 5 mg	7.5 ± 0.5 (S)^a	5/6/6^a	8.8 ± 0.5 (S)^a	6/6/6^a
L-arginine 100 mg	7.0 ± 0.0 (M)^a	4/5/5^a	7.5 ± 0.3 (M)^a	5/6/6^a
L-arginine 100 mg	7.0 ± 0.0 (S)	4/5/5^a	8.0 ± 0.4 (S)^a	5/6/6^a
L-NAME 5 mg +	7.3 ± 0.5 (M)	5/6/6^a	8.0 ± 0.3 (M)	5/6/6^a
L-arginine 100 mg	7.3 ± 0.5 (S)	5/6/6^a	8.2 ± 0.5 (S)	5/6/6^a
L-NAME 5 mg + BPC 157 10 μg	3.0 ± 0.0 (M)^a	1/1/1^a	0.0 ± 0.0 (M)^a	1/1/2^a
L-NAME 5 mg + BPC 157 10 μg	3.0 ± 0.0 (S)^a	1/1/1^a	0.0 ± 0.0 (S)^a	1/1/2^a
L-arginine 100 mg + BPC 157 10 μg	3.0 ± 0.0 (M)^a	1/1/1^a	0.0 ± 0.0 (M)^a	1/1/2^a
L-arginine 100 mg + BPC 157 10 μg	3.0 ± 0.0 (S)^a	1/1/1^a	0.0 ± 0.0 (S)^a	1/1/2^a
L-NAME 5 mg + L-arginine 100 mg + BPC 157 10 μg	3.0 ± 0.0 (M)^a	0/1/1^a	0.0 ± 0.0 (M)^a	1/1/2^a
L-NAME 5 mg + L-arginine 100 mg + BPC 157 10 μg	3.0 ± 0.0 (S)^a	0/1/1^a	0.0 ± 0.0 (S)^a	1/1/2^a

At 1 min post-injury, administration of medication (/kg, 10 mL/2 min bath/rat) at the perforated (5 mm diameter) lesion and cecum, includes BPC 157 (10 µg), NOS-blocker L-NAME (5 mg), NOS-substrate L-arginine (100 mg) alone or combined, a saline bath of equal volume (controls), and rats were left after abdominal closure undisturbed till the sacrifice, at day 1 or day 7. Minimum

P < 0.05 vs control.